BNP Paribas Financial Markets
TNXP icon

BNP Paribas Financial Markets’s Tonix Pharmaceuticals TNXP Stock Holding History

BNP Paribas Financial Markets’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$25.2K Sell
1,972
-890
-31% -$11.5K ﹤0.01% 5181
2026
Q1 		$39.4K Buy
2,862
+389
+16% +$5.99K ﹤0.01% 4814
2025
Q4 		$38.6K Buy
2,473
+745
+43% +$13.7K ﹤0.01% 4795
2025
Q3 		$41.7K Sell
1,728
-87
-5% -$3.23K ﹤0.01% 4673
2025
Q2 		$65.3K Buy
+1,815
New +$47.6K ﹤0.01% 4159
2025
Q1 		– Hold
0
– -$3 – 5587
2024
Q4 		– Hold
0
– – – 5382
2024
Q3 		– Hold
0
– – – 4136
2024
Q2 		– Hold
0
– – – 4022

Other funds holding TNXP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
II
Ishara Investments Los Angeles, California $136M AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BNP Paribas Financial Markets's TNXP Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Tonix Pharmaceuticals (TNXP) stake by 31% in Q2 2026, selling an estimated $11.5K and leaving 1,972 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #5181.

BNP Paribas Financial Markets first reported a position in TNXP in Q2 2025 and has held it in 5 quarters since. The position peaked at $65.3K in Q2 2025. 93 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

  • BNP Paribas Financial Markets held 1,972 shares of Tonix Pharmaceuticals worth $25.2K as of Q2 2026.
  • BNP Paribas Financial Markets sold 890 Tonix Pharmaceuticals shares in Q2 2026, an estimated $11.5K.
  • Tonix Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #5181 holding.
  • BNP Paribas Financial Markets first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • BNP Paribas Financial Markets's Tonix Pharmaceuticals position peaked at $65.3K in Q2 2025.
  • 93 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.